St. Joseph Hospital initiates enrollment in Medtronic’s SYMPLICITY HTN-3 trial for hypertension

The clinical trial is being conducted by Medtronic with its SYMPLICITY HTN-3, which is a randomized, controlled trial designed to evaluate the safety and effectiveness of renal denervation with the investigational Symplicity renal denervation system in patients with treatment-resistant hypertension and systolic blood pressure higher than 160 mmHg. Medtronic has enrolled about 80 patients nationally so far with the goal of entering 530 treatment-resistant hypertension patients across several U.S. medical centers during the next year.

People receiving the investigational treatment will be compared with a control group that does not, with all patients continuing to take their blood pressure medications. Patients enrolled in the SYMPLICITY HTN-3 trial will be randomly assigned to a group, with two out of three assigned to the treatment group and one out of three assigned to the control group. In addition, those in the control group may receive the treatment after a six-month period passes. The primary endpoints of the study are the change in blood pressure from baseline to six months and incidence of major adverse events.    

Source: St. Joseph Hospital of Orange